Hispanic dialysis patients face 40% higher risk of staph infection than whites, CDC says

Hispanic dialysis patients face 40% higher risk of staph infection than whites, CDC says


Hispanic dialysis patients face a 40% higher risk of developing a staph bloodstream infection compared with whites, underscoring economic and racial disparities in the U.S. health-care system, according to new data released Monday by the Centers for Disease Control and Prevention.

Adults on dialysis for kidney failure were 100 times more likely to contract staph bloodstream infections compared with the general U.S. population, the CDC said. Needles and catheters are used to connect patients to dialysis, and bacteria like staph can enter a patient’s bloodstream during the process. Staph infections are serious and sometimes deadly.

“Infections overall are thought to be the second-leading cause of death in dialysis patients — that’s all infections, not just bloodstream infections,” Dr. Shannon Novosad, head of the CDC’s dialysis safety team, told reporters during a call Monday. “They’re also one of the leading causes of hospitalizations for these patients.”

More than 800,000 people in the U.S. are living with kidney failure, 70% of whom are on dialysis, according to the CDC.

People of color, however, face an even higher risk of kidney failure, representing more than half of dialysis patients. The rate of kidney failure is four times higher among Black people and two times higher among Hispanics than white people, according to CDC data. Black people represent 33% of all patients in the U.S. on dialysis.

Black and Hispanic people on dialysis were also more likely to contract staph infections than white patients, the CDC said. The data analyzing dialysis patients from 2017 to 2020 didn’t clearly calculate the increased risk for Black patients. Hispanic patients, however, faced a 40% higher risk of staph infection than whites, according to the CDC.

More patients on dialysis with staph bloodstream infections lived in areas with higher poverty, more household crowding and lower education levels, Novosad said. About 42% of staph infections among dialysis patients occurred in areas with the highest levels of poverty, she said.

The CDC study looked at data from select counties in seven states from 2017 through 2020. The states are California, Connecticut, Georgia, Maryland, New York, Tennessee and Minnesota.

Bloodstream infections in patients on dialysis declined 40% from 2014 to 2019 due to staff and patient education on how to prevent them, according to the CDC. The use of fistulas and grafts to connect a patient’s blood circulation to the dialysis machine reduces the risk of infection compared with catheters.

“Preventing staph bloodstream infections begins by detecting chronic kidney disease in its early stages to prevent or delay the need for dialysis,” said CDC Chief Medical Officer Dr. Debra Houry.



Source

Inside politics of broken, unaffordable U.S. health care, Cityblock CEO Toyin Ajayi sees opportunity
Health

Inside politics of broken, unaffordable U.S. health care, Cityblock CEO Toyin Ajayi sees opportunity

For the first time in decades, people are having real conversations about health care, “from the ground up,” says Dr. Toyin Ajayi. That has her feeling optimistic. “We’re in a moment where health and health care — and what it means to be healthy — is the subject of a national discussion,” the co-founder and […]

Read More
Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq
Health

Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq

Methodiq brand advertisement. Courtesy: Methodiq Il Makiage parent company Oddity is branching out into medical-grade skin care with its new brand Methodiq, as the online retailer looks to compete with Hims and help to address what it called a “broken medical care system.”  Methodiq, which has been in the works for four years and launched […]

Read More
Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to 9 a month
Health

Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month

Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to […]

Read More